Kiniksa Enterprise Value Over E B I T D A from 2010 to 2024
| KNSA Stock | USD 21.41 0.09 0.42% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (49.58) | Current Value (47.10) | Quarterly Volatility 32.92595144 |
Check Kiniksa Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kiniksa Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 1.6 M, Interest Income of 1.6 M or Depreciation And Amortization of 1.9 M, as well as many indicators such as Price To Sales Ratio of 4.32, Dividend Yield of 0.0 or PTB Ratio of 2.94. Kiniksa financial statements analysis is a perfect complement when working with Kiniksa Pharmaceuticals Valuation or Volatility modules.
Kiniksa | Enterprise Value Over E B I T D A |
Latest Kiniksa Pharmaceuticals' Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Kiniksa Pharmaceuticals over the last few years. It is Kiniksa Pharmaceuticals' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kiniksa Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Kiniksa Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | (13.24) | |
| Geometric Mean | 17.45 | |
| Coefficient Of Variation | (248.78) | |
| Mean Deviation | 19.43 | |
| Median | (24.03) | |
| Standard Deviation | 32.93 | |
| Sample Variance | 1,084 | |
| Range | 144 | |
| R-Value | 0.23 | |
| Mean Square Error | 1,107 | |
| R-Squared | 0.05 | |
| Significance | 0.41 | |
| Slope | 1.67 | |
| Total Sum of Squares | 15,178 |
Kiniksa Enterprise Value Over E B I T D A History
About Kiniksa Pharmaceuticals Financial Statements
Kiniksa Pharmaceuticals stakeholders use historical fundamental indicators, such as Kiniksa Pharmaceuticals' Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although Kiniksa Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Kiniksa Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Kiniksa Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Kiniksa Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (49.58) | (47.10) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kiniksa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kiniksa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kiniksa Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kiniksa Pharmaceuticals Stock:Check out the analysis of Kiniksa Pharmaceuticals Correlation against competitors. For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiniksa Pharmaceuticals. If investors know Kiniksa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiniksa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.5 | Earnings Share (0.12) | Revenue Per Share 5.415 | Quarterly Revenue Growth 0.674 | Return On Assets (0.03) |
The market value of Kiniksa Pharmaceuticals is measured differently than its book value, which is the value of Kiniksa that is recorded on the company's balance sheet. Investors also form their own opinion of Kiniksa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiniksa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiniksa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiniksa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kiniksa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kiniksa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiniksa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.